MX2023013537A - Metodo de tratamiento de la enfermedad de alzheimer. - Google Patents

Metodo de tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2023013537A
MX2023013537A MX2023013537A MX2023013537A MX2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A
Authority
MX
Mexico
Prior art keywords
alzheimer
disease
treatment
hydrochloride
inden
Prior art date
Application number
MX2023013537A
Other languages
English (en)
Spanish (es)
Inventor
Sharon L Rogers
Original Assignee
Amyriad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amyriad Pharma Inc filed Critical Amyriad Pharma Inc
Publication of MX2023013537A publication Critical patent/MX2023013537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023013537A 2021-05-19 2022-05-19 Metodo de tratamiento de la enfermedad de alzheimer. MX2023013537A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163190299P 2021-05-19 2021-05-19
US202163192398P 2021-05-24 2021-05-24
US202263331011P 2022-04-14 2022-04-14
PCT/US2022/030020 WO2022246059A1 (en) 2021-05-19 2022-05-19 Method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2023013537A true MX2023013537A (es) 2024-02-06

Family

ID=84104208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013537A MX2023013537A (es) 2021-05-19 2022-05-19 Metodo de tratamiento de la enfermedad de alzheimer.

Country Status (8)

Country Link
US (3) US20220370443A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340834A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024518455A (cg-RX-API-DMAC7.html)
KR (1) KR20240021760A (cg-RX-API-DMAC7.html)
AU (1) AU2022275939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217579A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013537A (cg-RX-API-DMAC7.html)
WO (1) WO2022246059A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635652B1 (en) * 1999-07-30 2003-10-21 Zenyaku Kogyo Kabushiki Kaisha Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient
US20100168135A1 (en) * 2008-12-15 2010-07-01 Kim Nicholas Green Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
WO2012094615A2 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Use of cav3.1 selective t-type calcium channel antagonists

Also Published As

Publication number Publication date
WO2022246059A1 (en) 2022-11-24
US20240156812A1 (en) 2024-05-16
AU2022275939A1 (en) 2023-11-16
EP4340834A1 (en) 2024-03-27
KR20240021760A (ko) 2024-02-19
US20250375444A1 (en) 2025-12-11
US20220370443A1 (en) 2022-11-24
EP4340834A4 (en) 2025-04-02
JP2024518455A (ja) 2024-05-01
CA3217579A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
EE200100619A (et) Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
EP2270511A3 (en) Method of therapy
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
SE0202429D0 (sv) Novel Compounds
ITMI20022674A1 (it) Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
DE60328722D1 (de) Verfahren zur herstellung von tannat-tabletten, kapseln oder anderen festen dosierformen
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
ZA202309001B (en) Abhd6 antagonist
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
MX2025012741A (es) Composiciones farmaceuticas orales
EA200700178A1 (ru) Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
TW200510399A (en) 1, 3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
EA200700433A1 (ru) Производные бетулинола в качестве агентов против вич (вируса иммунодефицита человека)
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
UA85389C2 (ru) Применение циклических биоизостеров производных пуриновой системы для лечения расстройств, вызванных нарушениями нитрэргической и дофаминергической систем
DE60104589D1 (de) Therapeutisches Mittel zur Behandlung von Dermatitis